Mink Therapeutics, Inc. Stock Price, News & Analysis

MiNK Therapeutics (NASDAQ: INKT) will present late-breaking Phase 1 data for AgenT-797, an allogeneic iNKT cell therapy, at the 40th Annual Society for Immunotherapy of Cancer (SITC) meeting, November 7–9, 2025.

The poster (LBA #1344) titled “AgenT-797, an Allogeneic iNKT Cell Therapy, Demonstrates Durable Clinical Activity in Solid Tumors: Updated Phase 1 Findings” will report updated safety and efficacy results from the ongoing Phase 1 study in advanced solid tumors.

Presentation by Dr. Benjamin Garmezy will be in Prince George ABC Exhibit Halls, Gaylord National Resort & Convention Center, National Harbor, MD, on Saturday, November 8: poster attendance 12:15–1:45 PM ET and 5:10–6:35 PM ET.

MiNK Therapeutics (Nasdaq: INKT) has appointed Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb brings extensive expertise in trauma and critical care medicine, having served 23 years in the U.S. Army and authored over 780 peer-reviewed publications.

Dr. Holcomb joins alongside recently appointed pulmonary critical care expert Dr. Terese Hammond, strengthening MiNK's leadership as it develops invariant natural killer T (iNKT) cell therapies for immune-mediated diseases, pulmonary disorders, and global health security challenges. His expertise in trauma medicine, immune activation, and clinical trial execution will be valuable as MiNK advances its therapeutic programs into late-stage development.

MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, announced that CEO Dr. Jennifer Buell will deliver a plenary address at the 10th Annual CAR-TCR Summit in Boston, MA (September 23-26, 2025).

During her presentation, Dr. Buell will share first-in-human data from MiNK's iNKT platform, demonstrating durable disease reversal and steroid-free remission in severe immune collapse. The company's off-the-shelf approach is designed to be administered without HLA matching or lymphodepletion, focusing on treating autoimmunity and pulmonary failure.

MiNK Therapeutics (NASDAQ: INKT) has appointed Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases. Dr. Hammond, a renowned expert in pulmonary and critical care medicine, has been the lead author of MiNK's Nature Communications publication on their iNKT cell therapy (agenT-797) in acute respiratory distress syndrome (ARDS).

In her new role, Dr. Hammond will lead two priority programs: an upcoming grant-funded clinical trial in graft-versus-host disease (GVHD) and a planned late-stage trial in severe pulmonary disease. Her previous clinical work has shown meaningful survival benefits and reduced infectious complications in severe acute lung injury and life-threatening hypoxemic pneumonia.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company, reported significant Q2 2025 milestones and financial results. The company achieved a notable breakthrough with a durable complete remission in metastatic testicular cancer using their agenT-797 therapy, published in Nature's Oncogene.

MiNK secured substantial funding through two non-dilutive grants from the Department of Defense for GvHD research and raised $13 million through equity sales post-Q2, extending their cash runway beyond mid-2026. The company reported a Q2 2025 net loss of $4.2 million ($1.06 per share) compared to $2.7 million in Q2 2024, with cash and equivalents of $1.6 million at quarter-end.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing innovative invariant natural killer T (iNKT) cell therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, before market opening.

The company will host a conference call and webcast at 8:30 a.m. ET to discuss the quarterly results and provide a corporate update. Investors can access the call through dial-in numbers for New York (646-307-1963) and USA/Canada (800-715-9871) using Conference ID 1149380, or via webcast on the company's investor relations website.

MiNK Therapeutics (NASDAQ: INKT) announced a publication in Frontiers in Immunology highlighting their innovative iNKT cell therapy platform. The article focuses on their lead program agenT-797, an unmodified allogeneic iNKT therapy, which has shown promising results in solid tumors without requiring lymphodepletion or genetic modification.

The company reported a notable case where a patient with metastatic testicular cancer achieved complete remission using agenT-797 combined with anti-PD-1 therapy, remaining disease-free for over two years. Additionally, in a Phase 2 trial for second-line gastric cancer, the therapy demonstrated enhanced tumor infiltration and durable disease control.

MiNK is also advancing MiNK-215, an IL-15-armored, FAP-targeting CAR-iNKT cell therapy designed to overcome stromal barriers in resistant tumors.

MiNK Therapeutics (NASDAQ: INKT) announced a groundbreaking publication in Nature's Oncogene detailing a complete remission case in metastatic testicular cancer using their agenT-797 allogeneic iNKT cell therapy. The patient, who had previously failed multiple treatments including platinum-based chemotherapy and immunotherapies, achieved complete remission lasting over two years after a single infusion of agenT-797 with nivolumab.

The therapy demonstrated remarkable safety with no cytokine release syndrome or graft-versus-host disease. Additionally, MiNK presented promising Phase 2 trial data in gastric cancer showing extended survival beyond 12 months in several patients, with a separate case reporting 42% tumor reduction and nine months progression-free survival.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, has announced its Annual Shareholders Meeting will be held virtually on June 18, 2025, at 9:30 a.m. ET. Shareholders can participate by visiting www.virtualshareholdermeeting.com/INKT2025 using their 16-digit control number from proxy materials. Registration opens at 9:15 a.m. ET. Guests can access the meeting in listen-only mode without a control number. The meeting will be available via webcast on the company's investor relations website and the virtual shareholder meeting platform.